Kiniksa Pharmaceuticals International, plc (KNSA) stock
KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30473% above fair value
$93.53−1.52 (-1.59%)
Close on Nov 19, 2026Market cap $14.70BP/E 72.0Yield –
Kiniksa Pharmaceuticals International net income
Net income is the profit left for shareholders after every expense, interest and tax.
Kiniksa Pharmaceuticals International's net income for the twelve months ending Sep 30, 2026 was $109.57M, up 205.1% year over year. For fiscal 2025 it was $59.01M. The highest annual figure on record is $183.36M in fiscal 2022.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.01M | – |
| FY2024 | Dec 31, 2024 | -$43.19M | -406.7% |
| FY2023 | Dec 31, 2023 | $14.08M | -92.3% |
| FY2022 | Dec 31, 2022 | $183.36M | – |
| FY2021 | Dec 31, 2021 | -$157.92M | – |
| FY2020 | Dec 31, 2020 | -$161.38M | – |
| FY2019 | Dec 31, 2019 | -$161.87M | – |
| FY2018 | Dec 31, 2018 | -$103.23M | – |
| FY2017 | Dec 31, 2017 | -$64.87M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $47.35M | +156.8% |
| Q2 FY2026 | Jun 30, 2026 | $25.43M | +42.6% |
| Q1 FY2026 | Mar 31, 2026 | $22.59M | +164.6% |
| Q4 FY2025 | Dec 31, 2025 | $14.20M | – |
| Q3 FY2025 | Sep 30, 2025 | $18.44M | – |
| Q2 FY2025 | Jun 30, 2025 | $17.83M | – |
| Q1 FY2025 | Mar 31, 2025 | $8.54M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.89M | -135.2% |
| Q3 FY2024 | Sep 30, 2024 | -$12.69M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.91M | -126.1% |
| Q1 FY2024 | Mar 31, 2024 | -$17.70M | – |
| Q4 FY2023 | Dec 31, 2023 | $25.24M | +465.7% |
| Q3 FY2023 | Sep 30, 2023 | -$13.86M | -106.2% |
| Q2 FY2023 | Jun 30, 2023 | $14.97M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.27M | – |
| Q4 FY2022 | Dec 31, 2022 | $4.46M | – |
| Q3 FY2022 | Sep 30, 2022 | $224.09M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.98M | – |
| Q1 FY2022 | Mar 31, 2022 | -$25.21M | – |
| Q4 FY2021 | Dec 31, 2021 | -$36.33M | – |
| Q3 FY2021 | Sep 30, 2021 | -$30.54M | – |
| Q2 FY2021 | Jun 30, 2021 | -$41.56M | – |
| Q1 FY2021 | Mar 31, 2021 | -$49.48M | – |
| Q4 FY2020 | Dec 31, 2020 | -$53.66M | – |
| Q3 FY2020 | Sep 30, 2020 | -$43.84M | – |
| Q2 FY2020 | Jun 30, 2020 | -$37.47M | – |
| Q1 FY2020 | Mar 31, 2020 | -$26.42M | – |
| Q4 FY2019 | Dec 31, 2019 | -$31.80M | – |
| Q3 FY2019 | Sep 30, 2019 | -$27.06M | – |
| Q2 FY2019 | Jun 30, 2019 | -$37.19M | – |
| Q1 FY2019 | Mar 31, 2019 | -$65.82M | – |
| Q4 FY2018 | Dec 31, 2018 | -$42.58M | – |
| Q3 FY2018 | Sep 30, 2018 | -$24.41M | – |
| Q2 FY2018 | Jun 30, 2018 | -$20.26M | – |
| Q1 FY2018 | Mar 31, 2018 | -$15.98M | – |
| Q4 FY2017 | Dec 31, 2017 | -$32.70M | – |
| Q3 FY2017 | Sep 30, 2017 | -$16.03M | – |
| Q2 FY2017 | Jun 30, 2017 | -$11.20M | – |
See a number that looks wrong?